These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 35687336)

  • 1. Imaging Response to Contemporary Immuno-oncology Combination Therapies in Patients With Metastatic Renal Cell Carcinoma.
    Navani V; Ernst M; Wells JC; Yuasa T; Takemura K; Donskov F; Basappa NS; Schmidt A; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; Powles T; McKay RR; Weickhardt A; Suarez C; Kapoor A; Lee JL; Choueiri TK; Heng DYC
    JAMA Netw Open; 2022 Jun; 5(6):e2216379. PubMed ID: 35687336
    [TBL] [Abstract][Full Text] [Related]  

  • 2. First-line Immuno-Oncology Combination Therapies in Metastatic Renal-cell Carcinoma: Results from the International Metastatic Renal-cell Carcinoma Database Consortium.
    Dudani S; Graham J; Wells JC; Bakouny Z; Pal SK; Dizman N; Donskov F; Porta C; de Velasco G; Hansen A; Iafolla M; Beuselinck B; Vaishampayan UN; Wood LA; Liow E; Yan F; Yuasa T; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2019 Dec; 76(6):861-867. PubMed ID: 31445844
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Outcomes for International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Groups in Contemporary First-line Combination Therapies for Metastatic Renal Cell Carcinoma.
    Ernst MS; Navani V; Wells JC; Donskov F; Basappa N; Labaki C; Pal SK; Meza L; Wood LA; Ernst DS; Szabados B; McKay RR; Parnis F; Suarez C; Yuasa T; Lalani AK; Alva A; Bjarnason GA; Choueiri TK; Heng DYC
    Eur Urol; 2023 Jul; 84(1):109-116. PubMed ID: 36707357
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Checkpoint inhibitors in patients with metastatic renal cell carcinoma: Results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Yip SM; Wells C; Moreira R; Wong A; Srinivas S; Beuselinck B; Porta C; Sim HW; Ernst DS; Rini BI; Yuasa T; Basappa NS; Kanesvaran R; Wood LA; Canil C; Kapoor A; Fu SYF; Choueiri TK; Heng DYC
    Cancer; 2018 Sep; 124(18):3677-3683. PubMed ID: 30307610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world Assessment of Clinical Outcomes in Patients with Metastatic Renal Cell Carcinoma with or Without Sarcomatoid Features Treated with First-line Systemic Therapies.
    Sawaya GB; Dragomir A; Wood LA; Kollmannsberger C; Basappa NS; Kapoor A; Soulières D; Finelli A; Heng DYC; Castonguay V; Canil C; Winquist E; Graham J; Bjarnason GA; Bhindi B; Lalani AK; Pouliot F; Breau RH; Saleh R; Tanguay S
    Eur Urol Oncol; 2024 Jun; 7(3):570-580. PubMed ID: 38097481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
    Santoni M; Buti S; Myint ZW; Maruzzo M; Iacovelli R; Pichler M; Kopecky J; Kucharz J; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Kopp RM; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Massari F; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Sunela K; Bassanelli M; Ortega C; Grillone F; Landmesser J; Milella M; Messina C; Küronya Z; Mosca A; Bhuva D; Santini D; Vau N; Morelli F; Incorvaia L; Rebuzzi SE; Roviello G; Soares A; Bisonni R; Bimbatti D; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Battelli N; Bracarda S; Porta C
    Eur Urol Oncol; 2024 Feb; 7(1):102-111. PubMed ID: 37481365
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CABOSEQ: The Effectiveness of Cabozantinib in Patients With Treatment Refractory Advanced Renal Cell Carcinoma: Results From the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC).
    Navani V; Wells JC; Boyne DJ; Cheung WY; Brenner DM; McGregor BA; Labaki C; Schmidt AL; McKay RR; Meza L; Pal SK; Donskov F; Beuselinck B; Otiato M; Ludwig L; Powles T; Szabados BE; Choueiri TK; Heng DYC
    Clin Genitourin Cancer; 2023 Feb; 21(1):106.e1-106.e8. PubMed ID: 35945133
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination antiangiogenic tyrosine kinase inhibition and anti-PD1 immunotherapy in metastatic renal cell carcinoma: A retrospective analysis of safety, tolerance, and clinical outcomes.
    Laccetti AL; Garmezy B; Xiao L; Economides M; Venkatesan A; Gao J; Jonasch E; Corn P; Zurita-Saavedra A; Brown LC; Kao C; Kinsey EN; Gupta RT; Harrison MR; Armstrong AJ; George DJ; Tannir N; Msaouel P; Shah A; Zhang T; Campbell MT
    Cancer Med; 2021 Apr; 10(7):2341-2349. PubMed ID: 33650321
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical Effectiveness of Second-line Sunitinib Following Immuno-oncology Therapy in Patients with Metastatic Renal Cell Carcinoma: A Real-world Study.
    Wells JC; Dudani S; Gan CL; Stukalin I; Azad AA; Liow E; Donskov F; Yuasa T; Pal SK; De Velasco G; Hansen AR; Beuselinck B; Kollmannsberger CK; Powles T; McGregor BA; Duh MS; Huynh L; Heng DYC
    Clin Genitourin Cancer; 2021 Aug; 19(4):354-361. PubMed ID: 33863648
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cytoreductive nephrectomy in patients with synchronous metastases from renal cell carcinoma: results from the International Metastatic Renal Cell Carcinoma Database Consortium.
    Heng DY; Wells JC; Rini BI; Beuselinck B; Lee JL; Knox JJ; Bjarnason GA; Pal SK; Kollmannsberger CK; Yuasa T; Srinivas S; Donskov F; Bamias A; Wood LA; Ernst DS; Agarwal N; Vaishampayan UN; Rha SY; Kim JJ; Choueiri TK
    Eur Urol; 2014 Oct; 66(4):704-10. PubMed ID: 24931622
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Combination therapies in patients with favorable risk metastatic renal cell Carcinoma: A Systematic Review and Meta-Analysis.
    Bolek H; Yekedüz E; Ürün Y
    Cancer Treat Rev; 2024 Jan; 122():102667. PubMed ID: 38101099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Outcomes of First-line Sunitinib Followed by Immuno-oncology Checkpoint Inhibitors in Patients With Metastatic Renal Cell Carcinoma.
    Wells JC; Graham J; Beuselinck B; Bjarnason GA; Donskov F; Hansen AR; McKay RR; Vaishampayan U; De Velasco G; Duh MS; Huynh L; Nguyen C; Zanotti G; Ramaswamy K; Choueiri TK; Heng DYC
    Clin Genitourin Cancer; 2020 Aug; 18(4):e350-e359. PubMed ID: 31926879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of cytoreductive nephrectomy in metastatic renal cell carcinoma in immune-oncology era (SEVURO-CN): study protocol for a multi-center, prospective, randomized trial.
    Park JS; Kim J; Jeon J; Lee J; Jang WS; Lee SH; Han WK; Choi YD; Koo KC; Cho KS; Chung BH; Ham WS
    Trials; 2024 Jul; 25(1):447. PubMed ID: 38961439
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A U.S. Food and Drug Administration-pooled Analysis of Frontline Combination Treatment Survival Benefits by Risk Groups in Metastatic Renal Cell Carcinoma.
    Lee D; Gittleman H; Weinstock C; Suzman D; Bloomquist E; Agrawal S; Brave M; Brewer J; Fallah J; Singh H; Tang S; Ibrahim A; Pazdur R; Beaver JA; Amiri-Kordestani L
    Eur Urol; 2023 Oct; 84(4):373-378. PubMed ID: 37271635
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study.
    Santoni M; Massari F; Myint ZW; Iacovelli R; Pichler M; Basso U; Kopecky J; Kucharz J; Buti S; Rizzo M; Galli L; Büttner T; De Giorgi U; Kanesvaran R; Fiala O; Grande E; Zucali PA; Fornarini G; Bourlon MT; Scagliarini S; Molina-Cerrillo J; Aurilio G; Matrana MR; Pichler R; Cattrini C; Büchler T; Seront E; Calabrò F; Pinto A; Berardi R; Zgura A; Mammone G; Ansari J; Atzori F; Chiari R; Bamias A; Caffo O; Procopio G; Bassanelli M; Merler S; Messina C; Küronya Z; Mosca A; Bhuva D; Vau N; Incorvaia L; Rebuzzi SE; Roviello G; Zabalza IO; Rizzo A; Mollica V; Sorgentoni G; Monteiro FSM; Montironi R; Battelli N; Porta C
    Target Oncol; 2023 Jul; 18(4):559-570. PubMed ID: 37369815
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of Patients With Metastatic Renal Cell Carcinoma Experiencing Complete Response to First-line Therapies: Results From the International Metastatic Renal Cell Carcinoma Database Consortium.
    Takemura K; Navani V; Ernst MS; Wells JC; Meza L; Pal SK; Lee JL; Li H; Agarwal N; Alva AS; Hansen AR; Basappa NS; Szabados B; Powles T; Tran B; Hocking CM; Beuselinck B; Yuasa T; Choueiri TK; Heng DYC
    J Urol; 2023 Apr; 209(4):701-709. PubMed ID: 36573926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Real-World Assessment of Clinical Outcomes Among First-Line Sunitinib Patients with Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group.
    Savard MF; Wells JC; Graham J; Dudani S; Steinharter JA; McGregor BA; Donskov F; Bjarnason GA; Vaishampayan UN; Hansen AR; Iafolla MAJ; Zanotti G; Huynh L; Chang R; Duh MS; Heng DYC
    Oncologist; 2020 May; 25(5):422-430. PubMed ID: 31971318
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical outcomes in patients with metastatic renal cell carcinoma and brain metastasis treated with ipilimumab and nivolumab.
    Brown LC; Desai K; Wei W; Kinsey EN; Kao C; George DJ; Rini BI; Ornstein MC; Zhang T
    J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518292
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Outcomes of Patients with Metastatic Renal Cell Carcinoma Treated with Targeted Therapy After Immuno-oncology Checkpoint Inhibitors.
    Graham J; Shah AY; Wells JC; McKay RR; Vaishampayan U; Hansen A; Donskov F; Bjarnason GA; Beuselinck B; De Velasco G; Iafolla M; Duh MS; Huynh L; Chang R; Zanotti G; Ramaswamy K; Choueiri TK; Tannir NM; Heng DYC
    Eur Urol Oncol; 2021 Feb; 4(1):102-111. PubMed ID: 31786162
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real World Analysis of Peritoneal Metastasis From Renal Cell Carcinoma. Meet-Uro27.
    Stellato M; Buti S; Maruzzo M; Bassanelli M; Bersanelli M; Napoli MD; Dionese M; Fanelli M; Filippi R; Fotia G; Galli L; Grillone F; Maffezzoli M; Maiorano BA; Nasso C; Rebuzzi SE; Lalli L; Roviello G; Sorarù M; Vincenzi B; Procopio G; Verzoni E
    Clin Genitourin Cancer; 2024 Jun; 22(3):102078. PubMed ID: 38631104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.